CORRELATION OF SERUM PARATHORMONE WITH HYPERTENSION IN CHRONIC RENAL FAILURE PATIENTS UNDERGOING HEMODIALYSIS

Purpose: To consider. the effect of serum parathormone on severity of hypertension in end-stage renal failure patients undergoing hemodialysis treatment. Patients and Methods: A elms-sectional study was performed on patients with end-stage renal disease undergoing maintenance hemodialysis treatment. Serum calcium, phosphorus, alkalene phosphatase,secrum albumin and intact. PTH levels were measured. Stratification of hypertensive patients was performed from stage one to three. A stage of zero means the absence of hypertension. Stages of hypertension were measured before treatment. and at the beginning of the first hemodialysis treatment. Results: The total number of patients was 73 (F=28 M=45), including 58 non-diahetic (F=22 M=36) and 15 diabetic hemodialysis patients (F=6 M=9). The mean age of patients was 46.5 +/- 16 years. The mean period of time that patients had,spent on hemodialysis was 21.5 +/- 23.5 months. Serum iPTH of total patients was 309 +/- 349 pg/ml and serum alkaline phosphatase of total patients was 413 +/- 348 IU/L. There was a significant positive correlation between the stages (of hypertension and serum iPTH levels (r=0.200; p=0.045). There was no significant correlation between the stages (of hypertension and serum alkalene phosphatase levels (r=0.135; p=1128). A significant positive correlation between surges of hypertension:elision with Ca x P products of patients (r = 0.231; p = 0.027) was also seen. Conclusion: The relationship between serum iPTH and severity of hypertension in this group requires further research pm nontraditional causes of hypertension in hemodialysis patients. Hypertension and secondary hyperparathyroidism both interact in the process of accelerated atherosclerosis in hemodialysis patients. This combination may aggravate the rapid progressive athrosclerosis process.